1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


Delayed London Stock Exchange  -  05/20 11:35:10 am EDT
10494.00 GBX   +2.38%
05/20Astrazeneca's Healthy Heart Africa Screens 3.9 Million Ugandans for Hypertension
05/19EU health regulator backs using AstraZeneca COVID shot as booster
05/19ASTRAZENECA : Deutsche Bank gives a Buy rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

N.Korea gets offers of aid to fight COVID as it lacks vaccines

05/13/2022 | 03:25am EDT
FILE PHOTO: People wearing protective face masks walk amid concerns over the new coronavirus disease in Pyongyang, North Korea

SEOUL (Reuters) - North Korea is facing its first confirmed COVID-19 outbreak with no known vaccine programme, sparking new calls for the government to accept aid that could save lives, help protect its battered economy, and possibly lead to a diplomatic opening.

The office of South Korean President Yoon Suk-yeol said on Friday it intends to help the North, including by providing vaccines, and that specific measures would be discussed with Pyongyang.

North Korea is not known to have imported or administered any COVID-19 vaccines, and is one of only two countries that haven't begun a vaccination campaign. Until Thursday's reports by state news agency KCNA, it had never reported a confirmed case of the disease.

Its unexpected admission that infections were "exploding" across the nation led some observers to hope that Pyongyang might soon accept vaccines.

"Unveiling the outbreak through KCNA, which is a primary channel for external communications, indicates that North Korea could seek vaccine support," said Yang Moo-jin, a professor at the University of North Korean Studies in Seoul. "Isolation and control are not enough to overcome the crisis without vaccines."

Others said that it remains unclear whether North Korea's stance is softening, and that there are many hurdles with geopolitical implications.

Some analysts argue that "vaccine diplomacy" with North Korea could ease tensions in other areas such as the country's nuclear weapons and ballistic missile programmes.

"If inter-Korean cooperation does happen, it would help defuse military tension and reopen talks, and potentially lead to humanitarian exchanges such as a reunion of separated families," said Cheong Seong-chang, director of the Sejong Institute's North Korea studies centre in South Korea.

But the politicization of aid may also be a major reason why North Korea has been hesitant to accept.

Pyongyang might be more likely to reach out to its allies in Beijing first, Cheong said, though Pyongyang turned down an earlier offer of 3 million COVID-19 vaccine doses of China's Sinovac Biotech.

"If the situation gets more uncontrollable, it would be difficult to refuse Western support," he said.

Authorities in Pyongyang appeared suspicious that they would only get a limited amount of vaccine and then to be under pressure to accept more, an independent U.N. human rights investigator said in February.

South Korean officials have said that the North did not want Sinovac or British-Swedish Astrazeneca shots, preferring the U.S.-made Moderna and Pfizer instead, and that talks with the global vaccine-sharing scheme COVAX had stalled because the North refused to agree to indemnity clauses regarding side effects.

"But that was before the outbreak, and now they're in an emergency," Kwon Young-se, South Korea's nominee to be the unification minister responsible for inter-Korean ties, told a parliamentary confirmation hearing on Thursday.

If North Korea accepts, the international vaccine-sharing programme COVAX can provide doses to enable the country to catch up with international immunization targets, said a spokesperson for Gavi, the charity that helps operate the programme.

Thae Young-ho, a former North Korean diplomat who is now a South Korean lawmaker, called for Yoon to seek temporary sanctions exemptions during his upcoming summit with U.S. President Joe Biden to allow the shipment of fuel and power generators into the North.

"Everyone talks about vaccine support, but North Korea does not have the infrastructure to keep the vaccines in cold storage or energy to maintain the system," he said. "It's like giving rice to a household that doesn't have a cooker and firewood."

Washington said on Thursday it supports providing aid to North Korea, but that it had no current plans to share vaccines.

"We urge the DPRK to work with the international community to facilitate the rapid vaccination of its population," a State Department spokesperson told Reuters, using the initials of North Korea's official name, the Democratic People's Republic of Korea.

(Reporting by Josh Smith. Editing by Gerry Doyle)

By Josh Smith and Hyonhee Shin

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.38% 10494 Delayed Quote.20.93%
MODERNA, INC. -4.97% 136.25 Delayed Quote.-46.35%
PFIZER, INC. 3.59% 52.47 Delayed Quote.-11.14%
ZR (ZR) - CBE (ELECTRONIC)/C1 1.56% 17.25 End-of-day quote.17.33%
All news about ASTRAZENECA PLC
05/20Astrazeneca's Healthy Heart Africa Screens 3.9 Million Ugandans for Hypertension
05/19EU health regulator backs using AstraZeneca COVID shot as booster
05/19ASTRAZENECA : Deutsche Bank gives a Buy rating
05/18Kepler Cheuvreux Downgrades AstraZeneca to Hold From Buy
05/18Kepler Cheuvreux Drops AstraZeneca To Hold From Buy, Lifts PT
05/18AstraZeneca signs licence agreement with RQ Biotechnology for monoclonal antibodies aga..
05/18From storage to transport, hurdles to getting COVID vaccine to N.Koreans
05/17What you need to know about the coronavirus right now
05/17ASTRAZENECA : Deutsche Bank keeps its Buy rating
05/17AstraZeneca Obtains Exclusive Global License To Develop Antibodies Against COVID-19
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 43 737 M - -
Net income 2022 5 294 M - -
Net Debt 2022 22 519 M - -
P/E ratio 2022 38,3x
Yield 2022 2,25%
Capitalization 203 B 203 B -
EV / Sales 2022 5,15x
EV / Sales 2023 4,72x
Nbr of Employees 83 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Last Close Price 130,81 $
Average target price 143,15 $
Spread / Average Target 9,44%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC20.93%202 681
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707